OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Outlook Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026
$0.49+0.00 (+0.98%)
Close on Oct 19, 2026
- Market cap
- $67.41M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Outlook Therapeutics has not reported a dividend
No dividend per share appears in Outlook Therapeutics's annual filings since fiscal 2014.